PLUS vs VRTX · P/E 17, rev $2.07B vs P/E 30, rev $12.00B
ePlus inc (PLUS) versus Vertex Pharmaceuticals Inc (VRTX) — a side-by-side from cached financials, not a winner call.
ePlus inc (PLUS) is a software - application company listed on NASDAQ.
Vertex Pharmaceuticals Inc (VRTX) is a biotechnology company listed on US.
Latest reported PLUS revenue for 2025-03-31 was $2.07B. Net income was $108.0M. Revenue was down 7.0% from 2024-03-31 to 2025-03-31. PLUS currently screens at market cap $2.10B and trailing P/E 17.1.
Latest reported VRTX revenue for 2025-12-31 was $12.00B. Net income was $3.95B. Revenue was up 8.9% from 2024-12-31 to 2025-12-31. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
PLUS currently screens at market cap $2.10B and trailing P/E 17.1. VRTX currently screens at market cap $106.87B and trailing P/E 29.7.
Not investment advice. Open the PLUS and VRTX stock pages for the full models.
Not investment advice.